Skip to main content

Table 4 Profile of treatment-related toxicities

From: Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study

  ICRT arm
(n = 139)
IC/CCRT arm
(n = 78)
P-value
Grade 3–4 adverse events during IC, n (%)
 Hematological
  Leukopenia/neutropenia 26 (18.71) 20 (25.64) 0.23
  Thrombocytopenia 1 (0.72) 0 (0) 1.00
  Anemia 2 (1.44) 0 (0) 0.54
 Non-Hematological
  Nausea/vomiting/diarrhea 23 (16.55) 12 (15.38) 0.82
  Liver disfunction 0 (0) 2 (2.56) 0.13
  Kidney disfunction 0 (0) 0 (0) NA
Grade 3–4 adverse events during RT, n (%)
 Hematological
  Leukopenia/neutropenia 5 (3.60) 16 (20.51) < 0.001a
  Thrombocytopenia 2 (1.44) 4 (5.13) 0.19
  Anemia 2 (1.44) 2 (2.56) 0.30
 Non-Hematological
  Nausea/vomiting/diarrhea 3 (2.16) 32 (41.03) < 0.001a
  Skin reaction 58 (41.73) 39 (50.00) 0.24
  Mucositis 41 (29.50) 37 (47.44) 0.01a
 Grade 3–4 late toxicities
  Xerostomia 48 (34.53) 38 (48.72) 0.04a
  Ear (deafness/otitis) 39 (28.06) 27 (34.62) 0.31
  Cranial neuropathy 9 (6.47) 4 (5.13) 0.69
  Neck tissue damage 28 (20.14) 24 (30.77) 0.08
  1. IC induction chemotherapy, RT radiotherapy, ICRT induction chemotherapy plus radiotherapy, ICCCRT concurrent chemotherapy plus radiotherapy, NA none available
  2. astatistical significant